Phase I trial of diaziquone (AZQ) plus GM-CSF.
Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerate dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.
Hartmann
L C
LC
Mayo Clinic, Rochester, MN 55905, USA.
Ames
M M
MM
Reid
J M
JM
Richardson
R L
RL
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001388:Aziridines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016227:Benzoquinones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008545:Melanoma / Q000188:drug therapy; D009504:Neutrophils / Q000187:drug effects
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D015507:Drugs, Investigational; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C029108:diaziquone